Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803622 | 1.00 | LMNA (0.35) | LMNATHRBF2PRSS1PRSS2 | |
| SCHEMBL7947063 | 1.00 | LMNA (0.35) | LMNATHRBF2PRSS1PRSS2 | |
| SCHEMBL7638924 | 0.82 | LMNA (0.42) | LMNATHRBF2PRSS1PRSS2 | |
| SCHEMBL7640464 | 0.81 | LMNA (0.33) | LMNATHRBF2PRSS1PRSS2 | |
| SCHEMBL7638933 | 0.81 | LMNA (0.33) | LMNATHRBF2PRSS1PRSS2 | |
| SCHEMBL7803333 | 0.79 | THRB (0.32) | LMNATHRB | |
| SCHEMBL6256217 | 0.77 | THRB (0.31) | LMNATHRB | |
| SCHEMBL6257714 | 0.77 | THRB (0.31) | LMNATHRB | |
| SCHEMBL6328126 | 0.77 | LMNA (0.38) | LMNATHRB | |
| SCHEMBL3176852 | 0.77 | LMNA (0.38) | LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226578-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SHERING AG (DE) | 2007-06-05 | — | — | US | disclosed |
| US-6916461-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SCHERING AG (DE) | 2005-07-12 | — | — | US | disclosed |
| US-20050147563-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-07 | — | — | US | disclosed |
| US-20030232012-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SCHERING AG (DE) | 2003-12-18 | — | — | US | disclosed |
| US-6468502-B1 | PARAMAGNETIC MACROMOLECULES WITH HIGHER PROTON RELAXIVITY; LOWER DOSAGE AND INCREASED SIGNAL INTENSITY; DETECTING VASCULAR DISEASES; DIFFERENTIATING TISSUE BLOOD SUPPLY LEVELS; DISTINGUISHING MYOCARDIAL INFARCTION FROM ISCHEMIA | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-10-22 | — | — | US | disclosed |
| US-6180113-B1 | USED IN TUMOR THERAPY AND INTERVENTIONAL RADIOLOGY | SCHERING AG (DE) | 2001-01-30 | — | — | US | disclosed |
| EP-0861345-A1 | TREATMENT OF POLYAMIDE MATERIALS WITH PARTIAL FLUOROESTERS OR FLUOROTHIOESTERS OF MALEIC ACID POLYMERS AND SULFONATED AROMATIC CONDENSATES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-09-02 | — | — | EP | disclosed |
| EP-0851948-A1 | PARTIAL FLUOROESTERS OR THIOESTERS OF MALEIC ACID POLYMERS AND THEIR USE AS SOIL AND STAIN RESISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-07-08 | — | — | EP | disclosed |
| WO-1997011218-A1 | PARTIAL FLUOROESTERS OR THIOESTERS OF MALEIC ACID POLYMERS AND THEIR USE AS SOIL AND STAIN RESISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-03-27 | — | — | WO | disclosed |
| WO-1997011219-A1 | TREATMENT OF POLYAMIDE MATERIALS WITH PARTIAL FLUOROESTERS OR FLUOROTHIOESTERS OF MALEIC ACID POLYMERS AND SULFONATED AROMATIC CONDENSATES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147563-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | FABP1, FLOT1, AFF1 | LMNA 1611/4885THRB 2180/4885F2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.